Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus warfarin after pulmonary endarterectomy in CTEPH
IRCT20151227025726N22Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Warfarin control with Rivaroxaban intervention (2 arms). Primary endpoints: Incidence of recurrent thrombosis, Incidence of ischemic stroke and 1 more. Started Oct 2019; status: completed.
02
Drugs
rivaroxabanwarfarin
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on IRCT20151227025726N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N22.